These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of metastatic renal cell carcinoma. Reeves DJ; Liu CY Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348 [TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667 [TBL] [Abstract][Full Text] [Related]
8. Aldesleukin in advanced renal cell carcinoma. Schmidinger M; Hejna M; Zielinski CC Expert Rev Anticancer Ther; 2004 Dec; 4(6):957-80. PubMed ID: 15606326 [TBL] [Abstract][Full Text] [Related]
9. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma]. Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697 [TBL] [Abstract][Full Text] [Related]
11. Temsirolimus in renal cell carcinoma. Otto T; Eimer C; Gerullis H Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma. Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912 [TBL] [Abstract][Full Text] [Related]
13. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL Oncology; 2013; 84(2):123-6. PubMed ID: 23235386 [TBL] [Abstract][Full Text] [Related]
14. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Hutson TE; Quinn DI Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986 [TBL] [Abstract][Full Text] [Related]
15. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Atkins MB; Regan M; McDermott D Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028 [TBL] [Abstract][Full Text] [Related]
16. Improving the therapeutic index of IL-2. McDermott DF Clin Adv Hematol Oncol; 2010 Dec; 8(12):862-4. PubMed ID: 21326162 [No Abstract] [Full Text] [Related]
17. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. Shablak A; Sikand K; Shanks JH; Thistlethwaite F; Spencer-Shaw A; Hawkins RE J Immunother; 2011 Jan; 34(1):107-12. PubMed ID: 21150719 [TBL] [Abstract][Full Text] [Related]